Lymphoma Clinical Trials in Pittsburgh

Showing 261-280 of 571 trials

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

NCT04186637

This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.

Advanced Solid TumorLymphoma

Alpine Immune Sciences, Inc.62 participantsStarted Jun 2020

Scottsdale, Arizona, United States • New Haven, Connecticut, United States • Lafayette, Indiana, United States +7 more locations

RECRUITINGPhase 2< 1 mile

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04920617

This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.

Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-cell Lymphoma

ImmunoVaccine Technologies, Inc. (IMV Inc.)102 participantsStarted Jun 2021

Fountain Valley, California, United States • Boca Raton, Florida, United States • Hollywood, Florida, United States +47 more locations

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Lymphoma Trials in Other Cities

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Safety Study of SEA-CD40 in Cancer Patients

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Other Conditions in Pittsburgh